BioMarin Pharmaceutical Inc Company News
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its first-quarter result to...
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Insightful Analysis of Biomarin Pharmaceutical Inc's Strengths, Weaknesses, Opportunities, and Threats
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript April 24, 2024 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.71, expectations were $0.6. BioMarin Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name […]
BioMarin Pharmaceutical ( NASDAQ:BMRN ) First Quarter 2024 Results Key Financial Results Revenue: US$648.8m (up 8.8...
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
Q1 2024 Biomarin Pharmaceutical Inc Earnings Call
If you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks can range from pre-revenue startups to global pharmaceutical giants. All it takes is one treatment to put the company on the map and provide outsized returns for its shareholders. Biotech is one of those growth sectors that have the potential to provide multibagger returns to your portfolio. Many fortunes have been made with a fortuitous investment in a Biotech stock at the right time. That time
Explore key financial achievements and strategic directions from Biomarin's latest earnings call.
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Old Arcived News About BioMarin Pharmaceutical Inc
- 3 Convertible Bonds That Belong in Your Portfolio.
- 3 Drugs Stocks Pushing Industry Growth.
- 4 Top Jefferies Biotech and Specialty Pharma Growth Stocks to Buy Now.
- BioMarin Announces Approval of VIMIZIM(R). [GlobeNewswire] - SAN RAFAEL, Calif. -- BioMarin Pharmaceutical Inc. today announced the Ministry of Health, Labor and Welfare granted approval of the registration of VIMIZIM(R) (elosulfase alfa) for the treatment of patients ...
- BioMarin Fails to Win Approval for Drug to Treat Duchenne.
- BioMarin Gets Unfavorable View From Panel on Duchenne Drug.
- Biomarin Pharmaceutical (BMRN) Down In After-Hours Trading.
- Biomarin Pharmaceutical (BMRN) Down In Early Morning Trading.
- BioMarin Pharmaceutical (BMRN) Earnings Report: Q4 2015 Conference Call Transcript.
- BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E.
- BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement.
- BIOMARIN PHARMACEUTICAL INC Financials.
- BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York. [at noodls] - December 9, 2014 Company to Profile Key Pipeline and Commercial Portfolio Assets SAN RAFAEL, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst and ...
- BioMarin's VIMIZIM(R). [at noodls] - SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Agência Nacional de Vigilancia Sanitaria (ANVISA), or the National Health Surveillance ...
- BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome. [at noodls] - SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Agência Nacional de Vigilancia Sanitaria (ANVISA), or the National Health Surveillance ...
- BioMarin’s Share Price Falls on Negative Investor Sentiment.
- Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics.
- BMRN, INCY And ALXN, Pushing Drugs Industry Downward.
- CEO still bullish on drug for rare disease.
- FDA Committee Raises Concerns about Kyndrisa’s Efficacy, Safety.
- FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB. [at noodls] - SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for BMN ...
- FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B). [at noodls] - SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for BMN ...
- FDA Sets December 27, 2015, as Kyndrisa’s PDUFA Date.
- Hedge Funds Are Buying Macy’s, Inc..
- How Would Kyndrisa Treat Duchenne Muscular Dystrophy?.
- Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders.
- Morgan Stanley is Wrong: This Biotech Could Explode Higher.
- Pharma Investors Look for Lessons After BioMarin FDA Defeat.
- PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout. [PR Newswire] - WILMINGTON, Del., Dec. 12, 2014 /PRNewswire/ -- Rigrodsky & Long, P.A.: - Do you own shares of Prosensa Holding N.V. (NASDAQ GS: RNA )? - Did you purchase any of your shares prior to ...
- Soaring North Bay biotech company grabs Peninsula space to woo workers.
- The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB).
- Three Biotech Stocks for 2016.
- Today's Dead Cat Bounce Stock Is Biomarin Pharmaceutical (BMRN).
- Today's Weak On High Volume Stock: Biomarin Pharmaceutical (BMRN).
- Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock.
BioMarin Pharmaceutical Inc Short Company Overview:
BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin's subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology.
